PLx Pharma Winddown Past Earnings Performance
Past criteria checks 0/6
PLx Pharma Winddown's earnings have been declining at an average annual rate of -29.5%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 63.3% per year.
Key information
-29.5%
Earnings growth rate
-2.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 63.3% |
| Return on equity | -104.7% |
| Net Margin | -606.9% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How PLx Pharma Winddown makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 5 | -28 | 62 | 3 |
| 30 Jun 22 | 11 | -41 | 64 | 3 |
| 31 Mar 22 | 10 | -48 | 56 | 4 |
| 31 Dec 21 | 8 | -49 | 40 | 4 |
| 30 Sep 21 | 7 | -61 | 22 | 5 |
| 30 Jun 21 | 0 | -43 | 13 | 4 |
| 31 Mar 21 | 0 | -30 | 9 | 5 |
| 31 Dec 20 | 0 | -17 | 9 | 4 |
| 30 Sep 20 | 0 | -11 | 10 | 4 |
| 30 Jun 20 | 0 | -6 | 10 | 4 |
| 31 Mar 20 | 0 | -10 | 10 | 4 |
| 31 Dec 19 | 1 | -34 | 10 | 5 |
| 30 Sep 19 | 1 | -29 | 9 | 5 |
| 30 Jun 19 | 1 | -34 | 8 | 5 |
| 31 Mar 19 | 1 | -28 | 8 | 4 |
| 31 Dec 18 | 1 | 1 | 8 | 4 |
| 30 Sep 18 | 1 | -10 | 8 | 5 |
| 30 Jun 18 | 1 | -10 | 9 | 5 |
| 31 Mar 18 | 1 | -9 | 11 | 5 |
| 31 Dec 17 | 1 | -15 | 10 | 4 |
| 30 Sep 17 | 0 | -9 | 10 | 2 |
| 30 Jun 17 | 0 | -6 | 8 | 1 |
| 31 Mar 17 | 0 | -5 | 5 | 0 |
| 31 Dec 16 | 0 | -5 | 5 | 0 |
| 30 Sep 16 | 0 | -4 | 4 | 0 |
| 30 Jun 16 | 0 | -5 | 3 | 0 |
| 31 Mar 16 | 0 | -4 | 2 | 0 |
| 31 Dec 15 | 0 | -4 | 2 | 0 |
| 30 Sep 15 | 0 | -4 | 2 | 1 |
| 30 Jun 15 | 0 | -3 | 2 | 1 |
| 31 Mar 15 | 0 | -4 | 2 | 2 |
| 31 Dec 14 | 0 | -5 | 2 | 3 |
| 31 Dec 13 | 1 | -9 | 4 | 6 |
Quality Earnings: 1D5A is currently unprofitable.
Growing Profit Margin: 1D5A is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1D5A is unprofitable, and losses have increased over the past 5 years at a rate of 29.5% per year.
Accelerating Growth: Unable to compare 1D5A's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1D5A is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: 1D5A has a negative Return on Equity (-104.74%), as it is currently unprofitable.